Sbir FY25 concept award, targeting PLOD2 in undifferentiated pleomorphic sarcoma
Active Definitive Contract Awarded Last action
- Contract number
- 75N91025C00027
- Awardee
-
Syzonc, Inc. UEI JRJ6JNJ2CHF3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,878
Award facts
- Opportunity
-
- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2025 Pre-Solicitation · 75N91024R00013 · Posted Mar 28, 2024
- Contract value 100% obligated
- $299,878.00 Current and potential, with all options
- Completion date 52% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 55 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Philadelphia, PA 19104, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$55,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $354,878 |
About this award
The National Cancer Institute awarded a $299,878 definitive contract to Syzonc, Inc. on September 29, 2025, under a total small business set-aside for an SBIR FY25 Concept Award targeting PLOD2 in undifferentiated pleomorphic sarcoma.
The originating solicitation sought proposals from small business concerns to develop innovative and transformative technologies in therapeutic, preventative, diagnostic, or digital health areas for the treatment, detection, and diagnosis of pediatric and rare cancers. Eligible firms had no more than 500 employees including affiliates. The solicitation required identification of an anticipated product, the clinical problem, and targeted cancer type(s), along with initial proof-of-concept data, entrepreneurship enhancement, and a business model and commercialization plan. Place of performance is Philadelphia, PA. The contract carries a firm fixed price structure with an ultimate completion date of September 28, 2027.
Quick answers
Who was awarded contract 75N91025C00027?
75N91025C00027 was awarded to Syzonc, Inc. by National Cancer Institute (National Institutes of Health) on September 29, 2025.
How much is contract 75N91025C00027 worth?
The government has obligated $299,878 on 75N91025C00027.
Was contract 75N91025C00027 competed?
The extent of competition for 75N91025C00027 was full and open competition after exclusion of sources. The government received 55 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award